BioGaia earnings for the third quarter of 2026 showed sales rising 23% to SEK400 million and operating profit increasing 54% to approximately SEK132 million. Results released on October 22 showed a sharp improvement in operating profitability, although orders brought forward from the fourth quarter and foreign-exchange gains helped shape the comparison.
Key Takeaways
- The operating margin rose to 33% from 26%, despite a slightly lower gross margin.
- EMEA led regional growth, but a substantial, unquantified amount of orders arrived earlier than expected.
- Management retained a 34% long-term operating-margin target, not specific near-term guidance.
Table of Contents
- BioGaia earnings show stronger operating profitability
- Early EMEA orders complicate the fourth-quarter comparison
- Adult health outpaces pediatrics
- Working capital limits cash conversion
- Conclusion
BioGaia earnings show stronger operating profitability
Quarterly net sales increased from SEK327 million to SEK400 million, with growth of 23% both including and excluding currency effects. Earnings per share rose to SEK1.09 from SEK0.65, an increase of 67%.
Gross profit increased 20% to SEK292 million, but the gross margin slipped to 73% from 74%. The quarter benefited from SEK3.2 million in US tariff refunds. CFO Alexander Kotsinas attributed the softer gross margin to geographic and product mix rather than manufacturing costs.
Reported operating expenses rose just 2% to SEK159 million from SEK157 million, helping operating profit grow faster than sales. However, those expenses included a positive SEK14 million foreign-exchange gain on receivables. Adjusted operating expenses increased about 13%, reflecting higher marketing and selling activity.
BioGaia’s quarterly investor presentation archive includes Q3 2026 alongside earlier reporting periods. For the first nine months of 2026, sales reached SEK1,214 million, up 16% excluding currency effects, while the adjusted operating margin was 31%.
| Item | Details |
|---|---|
| Americas, January–September 2026 | 43% of sales; growth of 17% excluding currency effects. |
| EMEA, January–September 2026 | 35% of sales; growth of 26% excluding currency effects. |
| Asia Pacific, January–September 2026 | 22% of sales; growth of 2% excluding currency effects. |
Early EMEA orders complicate the fourth-quarter comparison
EMEA sales grew 38% excluding currency effects, ahead of 23% growth in the Americas and 8% in Asia Pacific. Expansion in direct markets, including France and the UK, supported EMEA’s performance.
CEO Theresa Agnew said a substantial amount of EMEA orders had been brought forward from the fourth quarter, mainly in pediatrics. She did not quantify the amount. That timing means the third-quarter growth rate should not be treated as a clean indication of the underlying pace heading into year-end.
Asia Pacific remained the slowest-growing region over the first nine months. Agnew nevertheless said the company expected strong year-over-year growth there in the fourth quarter, even against a strong prior-year comparison. That is management’s expectation, not a completed result.
Adult health outpaces pediatrics
Adult health sales grew 29% excluding currency effects in the quarter, compared with 21% for pediatrics. Agnew identified Prodentis as a growth driver in the US, Canada and Japan, while Protectis chewable tablets performed well in Hong Kong.
The pediatrics gross margin fell two percentage points in the quarter. Kotsinas said both geographic and product mix contributed, and rejected the suggestion that the early EMEA orders explained the weaker margin.
Agnew described the 34% operating-margin goal as a long-term target that BioGaia anticipated reaching over the next couple of years, rather than specific guidance. Management said marketing investment would continue, including in direct markets, while some selling costs would vary with sales.
Working capital limits cash conversion
Cash flow from operating activities fell to about SEK80 million as higher receivables, slightly higher inventory and lower payables absorbed cash. Stronger accounting profit therefore did not translate into a corresponding improvement in operating cash generation.
Investment activity also increased, driven by production and warehouse investment at BGI. The reported amount associated with investing activities reached SEK26 million for the first nine months, compared with SEK3 million a year earlier.
Conclusion
The next quarterly results will show how the early EMEA orders affect fourth-quarter sales and whether Asia Pacific delivers management’s expected acceleration. For BioGaia earnings, cash conversion and profitability excluding currency gains will also help clarify the strength of the improvement.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
